http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#Head
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#assertion
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#provenance
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#pubinfo
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#assertion
http://purl.obolibrary.org/obo/DOID_3908
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_3908
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00642
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#association
http://www.w3.org/2000/01/rdf-schema#label
alimta r in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic non squamous nsclc with no egfr or alk genomic tumor aberrations 1 1 in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non squamous non small cell lung cancer nsclc 1 1 as a single agent for the maintenance treatment of patients with locally advanced or metastatic non squamous nsclc whose disease has not progressed after four cycles of platinum based first line chemotherapy 1 1 as a single agent for the treatment of patients with recurrent metastatic non squamous nsclc after prior chemotherapy 1 1 limitations of use 1 1 initial treatment in combination with cisplatin of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery 1 2 alimta r in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non squamous non small cell lung cancer nsclc as a single agent for the maintenance treatment of patients with locally advanced or metastatic non squamous nsclc whose disease has not progressed after four cycles of platinum based first line chemotherapy as a single agent for the treatment of patients with recurrent metastatic non squamous nsclc after prior chemotherapy limitations of use see clinical studies 14 1 alimta is indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00642
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#provenance
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#pubinfo
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#sig
http://purl.org/nanopub/x/hasSignature
RNV1zFhHUtSnXEkJ6IVUmCov6gSh1SyCh3YMlG3mUPpLznuKMphhungJQvgAZvE94AeKUfgoeOLr6GSLM3uyHYPQfCiRPu+PDtRFvTHWPpwNp77+JGZbnegG6E5xhubamhrpH9+IKsF9K5BhWJVWGRuc0puICjHElu213WB4Q3E=
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ
http://purl.org/dc/terms/created
2021-06-13T15:11:50.971+02:00
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAfc1aTkHpTICGW8HhAp4KlYGRNdmoolplFFM5_in1ONQ
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs